STOCK TITAN

Olink Holding Ab (Publ) Stock Price, News & Analysis

OLK Nasdaq

Welcome to our dedicated page for Olink Holding Ab (Publ) news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding Ab (Publ) stock.

Olink Holding AB (OLK) drives innovation in proteomics through advanced biomarker discovery platforms that accelerate clinical research. This news hub provides investors and researchers with timely updates on scientific breakthroughs, financial developments, and strategic initiatives shaping the future of precision medicine.

Access authoritative reports on OLK's quarterly earnings, technology partnerships with leading biopharma companies, regulatory milestones for diagnostic tools, and expansions of its global research network. Our curated collection ensures transparent access to primary source materials and verified corporate announcements.

Key focus areas include platform enhancements for protein analysis, collaborations with academic medical centers, and clinical validation studies supporting therapeutic development. Users benefit from organized updates across OLK business units without promotional bias or speculative commentary.

Bookmark this page for streamlined tracking of OLK's contributions to next-generation healthcare solutions. Check regularly for essential updates that inform investment decisions and research strategies in the evolving proteomics sector.

Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) awarded the 2022 Novelties in Biomarkers prize to Maria Martin-Grau from the University of Valencia at the Biomarkers of the Future conference in Paris. This annual award, established in 2019, aims to promote young researchers in biomarker discovery. The theme for this year attracted over 30 submissions across various medical fields. The conference emphasized the importance of proteomics and the necessity for industry and academia to support young talents in expanding the field. Olink's initiative addresses the existing skills gap in proteomics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.93%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) has launched the Olink® Flex, a customizable product that allows users to select up to 21 human proteins for analysis using absolute quantification. The Olink® Flex offers significant advantages such as high specificity, sensitivity, and a broad dynamic range, while also enabling efficient workflows with minimal hands-on time. Customers can choose assays from over 200 biomarkers related to various diseases, facilitating targeted research in immunology, oncology, and more. This innovative product enhances Olink's portfolio and aims to meet diverse protein biomarker research needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) reported third-quarter 2022 revenues of $31.8 million, a 59% increase from the prior year. The company's Explore segment contributed $21.7 million or 68% of total revenue, while kits revenue surged 265% year-over-year to $13.4 million. Olink anticipates full-year 2022 revenue between $138 million and $142 million, reflecting strong growth rates. Adjusted EBITDA improved to ($1.7 million) versus ($7.5 million) in Q3 2021, demonstrating recovery. However, foreign currency headwinds impacted expectations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.52%
Tags
Rhea-AI Summary

Olink (Nasdaq: OLK) announced a significant milestone, surpassing 1,000 peer-reviewed publications utilizing its Proximity Extension Assay (PEA) technology. This achievement highlights the rapid adoption of Olink's protein biomarker solutions in scientific research, with over 230 articles published in 2022 alone. The technology is applicable to diverse research areas, including cardiovascular, metabolic, neurological, and immunological diseases, as well as COVID-19. Olink's scalable technology supports studies ranging from small sample analyses to large international projects, emphasizing its transformative role in proteomics and precision medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) announced participation in two upcoming investor events. The Olink Investor Day 2022 is scheduled for November 14 at 11:00 am ET, followed by the Canaccord Genuity MedTech Forum on November 17 at 2:00 pm ET. A live and archived webcast of the Investor Day will be accessible on Olink's website. Founded in 2016 and headquartered in Uppsala, Sweden, Olink focuses on advancing proteomics to enable scientific discoveries and improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
conferences
-
Rhea-AI Summary

On October 24, 2022, Olink Holding AB (Nasdaq: OLK) launched Olink® Insight, a new online platform designed to enhance proteomics data analysis. This platform features tools like Pathway Explorer, Annotation, and Normal Ranges, aimed at simplifying user experiences with protein studies. Olink's commitment to innovation is reflected in its collaboration with the scientific community to provide high-quality, actionable data. The platform will initially focus on cancer in its upcoming Disease Atlas, expanding to other diseases in the future.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) will announce its financial results for Q3 2022 on November 10, 2022, before the market opens. A conference call with company management will follow at 8:00 am ET, providing insights into the financial performance and strategic direction of the company. Interested investors can register online for the call, and a live webcast will also be available on Olink's website. The webcast will be archived for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.43%
Tags
conferences earnings
-
Rhea-AI Summary

Personalis, Inc. (NASDAQ: PSNL) has partnered with Duke University and Olink Proteomics AB to research the effects of immunotherapy on advanced gastroesophageal cancer. The collaboration aims to identify composite biomarkers to enhance therapeutic decision-making. Gastroesophageal cancer is prevalent, with nearly 50% of patients facing advanced stages at diagnosis. Key goals include understanding responses to pembrolizumab, an approved immunotherapy, and developing strategies to optimize treatment effectiveness. The study will leverage Personalis' cutting-edge technology for comprehensive tumor profiling.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.55%
Tags
none
-
Rhea-AI Summary

Olink Holding AB (Nasdaq: OLK) has partnered with Discovery Life Sciences to create the largest commercial platform for Olink's technology in the Americas, enhancing proteomics research capabilities. This collaboration aims to facilitate the discovery and validation of protein biomarkers, bridging the gap between genomics and phenotypes. Olink's PEA technology will complement Discovery's existing services, including genomic and tissue biomarkers, improving drug development processes. This strategic alliance is positioned to expand Olink's market reach and support precision medicine initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
partnership
Rhea-AI Summary

On September 20, 2022, Discovery Life Sciences announced a major collaboration with Olink Holding AB to install the largest commercial platform of Olink's PEA technology in the Americas. This partnership aims to enhance biomarker discovery and validation services, positioning Discovery as a leading global certified service provider. The Olink PEA technology supports high-specificity proteomics, offering dual readout options like next-generation sequencing and qPCR. This installation significantly expands Discovery's multi-omic capabilities, furthering their commitment to innovation in precision medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none

FAQ

What is the current stock price of Olink Holding Ab (Publ) (OLK)?

The current stock price of Olink Holding Ab (Publ) (OLK) is $26.08 as of February 7, 2025.

What is the market cap of Olink Holding Ab (Publ) (OLK)?

The market cap of Olink Holding Ab (Publ) (OLK) is approximately 3.2B.
Olink Holding Ab (Publ)

Nasdaq:OLK

OLK Rankings

OLK Stock Data

3.24B
41.90M
66.41%
35.24%
2.03%
Diagnostics & Research
Healthcare
Link
Sweden
Uppsala